EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Nutra Pharma's enterprise value is $8.81 Mil.
Nutra Pharma's EBITDA for the trailing twelve months (TTM) ended in Sep. 2022 was $7.93 Mil. Therefore, Nutra Pharma's EV-to-EBITDA for today is 1.11.
The historical rank and industry rank for Nutra Pharma's EV-to-EBITDA or its related term are showing as below:
NPHC'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 0 Med: 0 Max: 1.11
Current: 1.11
During the past 13 years, the highest EV-to-EBITDA of Nutra Pharma was 1.11. The lowest was 0.00. And the median was 0.00.
NPHC's EV-to-EBITDA is not ranked
in the Drug Manufacturers industry.
Industry Median: 14.065
vs NPHC: 1.11
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Nutra Pharma EV-to-EBITDA Historical Data
The historical data trend for Nutra Pharma's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Nutra Pharma's EV-to-EBITDA
For the Drug Manufacturers - Specialty & Generic subindustry, Nutra Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nutra Pharma's EV-to-EBITDA Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nutra Pharma's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Nutra Pharma's EV-to-EBITDA falls into.
Nutra Pharma EV-to-EBITDA Calculation
Nutra Pharma's EV-to-EBITDA for today is calculated as:
Nutra Pharma's current Enterprise Value is $8.81 Mil.
Nutra Pharma's EBITDA for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.93 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Nutra Pharma's PE Ratio for today is calculated as:
Nutra Pharma's share price for today is $0.0001.
Nutra Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Nutra Pharma's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Nutra Pharma Corp operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. It also develops proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), and pain in humans. Some of its drug names are Cobroxin, Nyloxin, RPI-78M, RPI-MN and Pet Pain-Away.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NPHC has been successfully added to your 